1. Home
  2. Infectious disease topics
  3. Related public health topics
  4. Antimicrobial consumption
  5. Surveillance and disease data
  6. Antimicrobial consumption database
  7. Quality indicators for consumption in the community

Quality indicators for antibiotic consumption in the community

DAMC07
Quality indicators for antibiotic consumption in the community (primary care sector) in Europe 2020
 
Consumption
Relative consumption
Broad/narrow
Seasonal variation
Country
J01*
JO1C
J01D
J01F
J01M
J01CE_%
J01CR_%
J01DD+DE_%
J01MA_%
J01_B/N
J01_SV
J01M_SV
Austria
7.11
3.35
0.96
1.42
0.57
4.5%
32.9%
1.5%
8.0%
7.33
36.7%
25.0%
Belgium
15.25
6.97
0.80
2.65
0.46
<0.1%
23.5%
<0.1%
3.0%
264.21
54.7%
36.2%
Bulgaria
20.74
4.70
3.97
5.72
3.35
0.1%
9.5%
5.9%
16.1%
77.67
-
-
Croatia
14.05
6.16
2.09
2.44
1.22
1.7%
33.6%
3.1%
8.7%
17.22
46.1%
16.9%
Cyprus**
28.92
8.31
6.19
2.62
7.34
0.7%
23.5%
3.8%
25.4%
30.49
-
-
Czechia**
13.38
4.47
1.91
2.73
0.60
7.3%
21.5%
1.3%
4.5%
6.90
-
-
Denmark
12.51
8.08
0.03
1.20
0.33
22.2%
4.2%
<0.1%
2.6%
0.62
15.5%
12.3%
Estonia
8.81
3.18
1.02
1.80
0.72
1.2%
20.2%
<0.1%
8.2%
18.69
50.6%
20.4%
Finland
9.95
3.07
1.50
0.43
0.39
8.8%
4.6%
<0.1%
3.9%
0.40
27.7%
15.9%
France
18.70
10.10
0.88
2.34
1.09
0.9%
19.5%
3.9%
5.8%
29.40
-
-
Germany
8.95
3.05
1.68
1.31
0.49
4.9%
8.7%
2.2%
5.5%
7.67
41.8%
19.3%
Greece
26.37
8.69
5.76
5.06
2.61
<0.1%
17.7%
0.9%
9.9%
606.94
-
-
Hungary
10.03
3.16
1.38
2.24
1.41
0.5%
26.8%
2.4%
14.0%
104.30
52.8%
53.7%
Iceland
15.38
7.02
0.49
1.14
0.49
8.8%
9.6%
<0.1%
3.2%
1.27
28.9%
9.9%
Ireland
17.09
7.35
0.96
2.93
0.42
5.1%
13.0%
0.1%
2.5%
3.77
58.3%
26.5%
Italy
16.50
7.37
1.68
3.56
1.67
<0.1%
35.5%
9.0%
10.1%
205.58
53.4%
32.7%
Latvia
9.97
3.60
0.41
1.65
0.77
0.4%
17.4%
0.3%
7.8%
28.79
76.1%
20.9%
Liechtenstein
            
Lithuania
11.92
4.90
1.18
1.67
0.73
0.9%
9.9%
<0.1%
6.1%
16.33
-
-
Luxembourg
14.84
6.04
1.75
2.47
1.27
<0.1%
23.4%
0.1%
8.5%
130.60
-
-
Malta
14.38
5.17
2.00
2.45
1.36
0.9%
32.7%
3.4%
9.5%
45.33
-
-
Netherlands
7.77
2.39
0.03
1.36
0.64
1.6%
10.4%
<0.1%
8.2%
14.35
-
-
Norway
12.76
4.78
0.05
0.65
0.24
17.7%
0.3%
<0.1%
1.9%
0.18
-
-
Poland
17.15
4.42
2.32
2.76
1.15
1.1%
12.5%
0.4%
6.7%
34.27
-
-
Portugal
13.71
6.68
1.36
2.03
1.21
<0.1%
37.4%
1.0%
8.8%
78.38
56.0%
28.5%
Romania
23.75
10.46
3.86
4.53
2.96
2.1%
28.7%
3.6%
12.5%
23.93
-
-
Slovakia
13.15
3.27
3.30
3.30
1.14
4.2%
17.9%
4.6%
8.6%
13.37
-
-
Slovenia
8.85
4.72
0.41
1.34
0.84
8.1%
27.5%
0.5%
9.5%
5.45
39.5%
15.5%
Spain
18.21
9.91
1.92
2.05
1.78
0.3%
30.6%
2.7%
9.8%
57.52
-
-
Sweden
8.92
4.47
0.05
0.50
0.49
22.4%
2.1%
<0.1%
5.5%
0.31
-
-
United Kingdom
            
* Denominator for relative consumption; ** Country provided only total care data
Total care includes data both from the hospital and community sectors and overestimates the figures when used for reporting for the community sector.
The quality indicators presented should not be used alone to evaluate the effect of programmes towards prudent use in the community. These indicators are not applicable for the hospital sector.
Quality indicators
Consumption
J01
J01_DID***
Consumption of antibacterials for systemic use (J01) expressed in DDD per 1000 inhabitants and per day
J01C
J01C_DID
Consumption of penicillins (J01C) expressed in DDD per 1000 inhabitants and per day
J01D
J01D_DID
Consumption of cephalosporins (J01D) expressed in DDD per 1000 inhabitants and per day
J01F
J01F_DID
Consumption of macrolides, lincosamides and streptogramins (J01F) expressed in DDD per 1000 inhabitants and per day
J01M
J01M_DID
Consumption of quinolones (J01M) expressed in DDD per 1000 inhabitants and per day
Relative consumption
J01CE
J01CE_%
Consumption of beta-lactamase sensitive penicillins (J01CE) expressed as percentage of the total consumption of antibacterials for systemic use (J01)
J01CR
J01CR_%
Consumption of combination of penicillins, including beta-lactamase inhibitor (J01CR) expressed as percentage of the total consumption of antibacterials for systemic use (J01)
J01DD+DE
J01DD+DE_%
Consumption of third- and fourth-generation cephalosporins (J01(DD+DE)) expressed as percentage of the total consumption of antibacterials for systemic use (J01)
J01MA
J01MA_%
Consumption of fluoroquinolones (J01MA) expressed as percentage of the total consumption of antibacterials for systemic use (J01)
Broad/narrow
J01
J01_B/N
Ratio of the consumption of broad-spectrum (J01(CR+DC+DD+(F-FA01))) to the consumption of narrow-spectrum penicillins, cephalosporins and macrolides (J01(CE+DB+FA01))
Seasonal variation
J01
J01_SV
Seasonal variation of the total antibiotic consumption (J01)
Seasonal variation: Overuse in the winter quarters (January-March and October-December) compared with the summer quarters (April-June and July-September) of a 1-year period starting in July and ending the next calendar year in June, expressed as percentage: [DDD per 1000 inhabitants and per day (winter quarters)/DDD per 1000 inhabitants and per day (summer quarters)-1] x100
J01M
J01M_SV
Seasonal variation of quinolone consumption (J01M)
*** This column displays the original labels of the quality indicators as described in the article Coenen S, Ferech M, Haaijer-Ruskamp FM, et al. European Surveillance of Antimicrobial Consumption (ESAC): quality indicators for outpatient antibiotic use in Europe. published in Qual Saf Health Care 2007;16:440?445.
General comments for comparison of antimicrobial consumption data from different countries and/or years:
Total care includes data both from the hospital sector and community (primary care sector) and overestimates the figures when used for reporting for the community sector.
Some countries report reimbursement data that do not include consumption of antimicrobials obtained without prescription and other non-reimbursed courses.
For more information please see the report "Data source overview of antimicrobial consumption"
Finland: hospital sector data include consumption in remote primary health care centres and nursing homes, thus overestimating hospital consumption and underestimating community consumption compared to the other countries that report data from these sources as community consumption.
This report has been generated from ESAC-Net data submitted to TESSy, The European Surveillance System on 2022-08-12. The report reflects the state of submissions in TESSy as of 2022-08-11 at 21:17